Show simple item record

dc.contributor.authorVan Der Meulen, M.
dc.contributor.authorKapidzic, A.
dc.contributor.authorVan Leerdam, M.
dc.contributor.authorVan Der Steen, A.
dc.contributor.authorKuipers, E.
dc.contributor.authorSpaander, M.
dc.contributor.authorDe Koning, H.
dc.contributor.authorHol, L.
dc.contributor.authorLansdorp_Vogelaar, Iris
dc.date.accessioned2017-09-27T10:21:34Z
dc.date.available2017-09-27T10:21:34Z
dc.date.created2017-09-27T09:48:12Z
dc.date.issued2017
dc.identifier.citationVan Der Meulen, M. and Kapidzic, A. and Van Leerdam, M. and Van Der Steen, A. and Kuipers, E. and Spaander, M. and De Koning, H. et al. 2017. Do men and women need to be screened differently with fecal immunochemical testing? A cost-effectiveness analysis, 46th Annual Digestive Disease Week (DDW), pp. 1328-1336.
dc.identifier.urihttp://hdl.handle.net/20.500.11937/56935
dc.identifier.doi10.1158/1055-9965.EPI-16-0786
dc.description.abstract

© 2017 American Association for Cancer Research. Background: Several studies suggest that test characteristics for the fecal immunochemical test (FIT) differ by gender, triggering a debate on whether men and women should be screened differently. We used the microsimulation model MISCAN-Colon to evaluate whether screening stratified by gender is cost-effective. Methods: We estimated gender-specific FIT characteristics based on first-round positivity and detection rates observed in a FIT screening pilot (CORERO-1). Subsequent ly, we used the model to estimate harms, benefits, and costs of 480 genderspecific FIT screening strategies and compared them with uniform screening. Results: Biennial FIT screening from ages 50 to 75 was less effective in women than men [35.7 vs. 49.0 quality-adjusted life years (QALY) gained, respectively] at higher costs (€42, 161 vs. -€5, 471, respectively). However, the incremental QALYs gained and costs of annual screening compared with biennial screening were more similar for both genders (8.7 QALYs gained and €26, 394 for women vs. 6.7 QALYs gained and €20, 863 for men). Considering all evaluated screening strategies, optimal gender-based screening yielded at most 7% more QALYs gained than optimal uniform screening and even resulted in equal costs and QALYs gained from a willingness- to-pay threshold of €1, 300. Conclusions: FIT screening is less effective in women, but the incremental cost-effectiveness is similar in men and women. Consequently, screening stratified by gender is not more costeffective than uniform FIT screening. Impact: Our conclusions support the current policy of uniform FIT screening. Cancer Epidemiol Biomarkers Prev; 26(8); 1328-36.

dc.titleDo men and women need to be screened differently with fecal immunochemical testing? A cost-effectiveness analysis
dc.typeConference Paper
dcterms.source.volume26
dcterms.source.startPage1328
dcterms.source.endPage1336
dcterms.source.issn1055-9965
dcterms.source.titleCancer Epidemiology Biomarkers and Prevention
dcterms.source.seriesCancer Epidemiology Biomarkers and Prevention
dcterms.source.conference46th Annual Digestive Disease Week (DDW)
curtin.departmentCentre for Behavioural Research in Cancer Control
curtin.accessStatusFulltext not available


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record